Thus, several researchers are exploring the use of STING (cGAS/stimulator of interferon genes) or TLR (toll-like receptor) agonists, with or without NPs, for reprogramming TAMs in a variety of solid tumors.5 6 Although STING and TLR agonists are natural triggers of innate and adaptive immune responses, applying them for cancer immunotherapy is not an easy task. This evidence concerns the gene STING1 and cancer.